spark biopharma
was found in 2016 to provide new solution for improving human health by transferring the novel technology platform developed in the CRI center for Chemical Proteomics at Seoul National University to the real drug discovery process.
SPARK BIOPHARMA, Inc. envisions that the fundamental understanding of human disease in the molecular levels can help to create the new foundation for the generation of first-in-class small-molecule therapeutics through the integration of biology, chemistry, proteomics and informatics.
was found to seize the opportunity from the technological breakthrough that was achieved in the CRI center for Chemical Proteomics over 14 years at Seoul National University.
These technological platform was developed to systematically provide the novel bioactive small molecules to modulate the mysterious biological systems, especially related to human diseases. The traditional drug discovery process has been focused on the target-based approach to develop the best-in-class drugs against the proven therapeutic targets, which was not designed to seeking the first-in-class therapeutics. Therefore, it is essential to make a frame shift for the novel discovery of first-in-class therapeutics with new mode of actions.
SPARK BIOPHARMA, Inc.
established three unique technology platform to address this issue:
01
Molecular Diversity
using pDOS strategy,
02
Phenotype-based Drug
Discovery with novel
screening platform using
fluorescent bioprobes,
03
Target Identification and
Mode-of-Action
study of drug candidate
These novel technology platforms can be applied in various disease areas and create novel first-in-class drug candidates with new mode-of-action. In addition, our elucidation of mode-of-actions using quantitative proteomics and metabolomics can provide the unique biomarkers for the development of companion diagnosis systems of our therapeutic agents.